William Blair Small-Mid Cap Core Fund on Twist Bioscience Corp.
Thesis
Twist Bioscience's moat is based on miniaturized DNA manufacturing on silicon, allowing chemical reactions to occur at a scale beyond legacy technologies. The company is seeing broad momentum in DNA Synthesis and Protein Solutions as well as Next Generation Sequencing. AI-enabled drug discovery is a tailwind because pharmaceutical customers value the platform's speed, quality and cost advantages, while margins are moving toward profitability targets. The fund trimmed the position but continues to believe the secular shift toward synthetic biology should support sustainable share gains.
“Twist’s value proposition of high-throughput, high quality and low-cost pricing is differentiated and should allow for sustainable share gains”